PPT Slide

Alfimeprase Phase 2 Trial: PAO

Progress: Successfully completed the planned interim analysis

Interim analysis of the first 36 patients completed by the Data Safety and Monitoring Board (DSMB)

DSMB recommendation to move forward with all three doses, 0.1, 0.3 and 0.6 mg/kg

All three doses worthy of continued investigation from a safety and efficacy standpoint

Previous slide

Next slide

Back to first slide

View graphic version